0001140361-21-037655.txt : 20211112
0001140361-21-037655.hdr.sgml : 20211112
20211112161621
ACCESSION NUMBER: 0001140361-21-037655
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211109
FILED AS OF DATE: 20211112
DATE AS OF CHANGE: 20211112
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Malier Vanessa
CENTRAL INDEX KEY: 0001891515
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41008
FILM NUMBER: 211403713
MAIL ADDRESS:
STREET 1: 1209 ORANGE STREET
CITY: WILLMINGTON
STATE: DE
ZIP: 19801
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IO Biotech, Inc.
CENTRAL INDEX KEY: 0001865494
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 870909276
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: OLE MAALOES VEH 3
CITY: COPENHAGEN
STATE: G7
ZIP: 2200
BUSINESS PHONE: 4570702980
MAIL ADDRESS:
STREET 1: OLE MAALOES VEH 3
CITY: COPENHAGEN
STATE: G7
ZIP: 2200
4
1
form4.xml
FORM 4
X0306
4
2021-11-09
0001865494
IO Biotech, Inc.
IOBT
0001891515
Malier Vanessa
C/O IO BIOTECH, INC.
OLE MAALOES VEH 3
COPENHAGEN
G7
2200
DENMARK
true
Common Stock
2021-11-09
4
C
0
796059
A
796059
I
See footnote
Common Stock
2021-11-09
4
C
0
267977
A
267977
I
See footnote
Common Stock
2021-11-09
4
P
0
162500
14
A
958559
I
See footnote
Common Stock
2021-11-09
4
P
0
162500
14
A
430477
I
See footnote
Series C Preferred Stock
2021-11-09
4
C
0
63350
0
D
Common Stock
796059
0
I
See footnote
Series C Preferred Stock
2021-11-09
4
C
0
21325
0
D
Common Stock
267977
0
I
See footnote
Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date.
The securities are held by Kurma Biofund III FPCI. Kurma Partners is the management company of Kurma Biofund III FPCI. The reporting person is a member of the board of directors of Kurma Partners, and may be deemed to share voting and investment power with respect to the shares beneficially owned by Kurma Biofund III FPCI and disclaims Section 16 beneficial ownership of such securities held by Kurma Biofund III FPCI, except to the extent of her pecuniary interest therein, if any.
The securities are held by SKCI FPCI. Kurma Partners is the management company of SKCI FPCI. The reporting person is a member of the board of directors of Kurma Partners, and may be deemed to share voting and investment power with respect to the shares beneficially owned by SKCI FPCI and disclaims Section 16 beneficial ownership of such securities held by SKCI FPCI, except to the extent of her pecuniary interest therein, if any.
/s/ Brian Burkavage, Attorney-in-Fact for Vanessa Malier
2021-11-12